Impact of age, tumor size, lymph node metastasis, stage, receptor status and menopausal status on overall survival of breast cancer patients in Pakistan

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 3, 2015, Pages 1019-1024

  Mahmood, Humera ^a   Faheem, Mohammad ^a   Mahmood, Sana ^a   Sadiq, Maryam ^b   Irfan, Javaid ^a  

^a PAKISTAN ATOMIC ENERGY COMMISSION   (Pakistan)

^b UNIVERSITY OF AZAD JAMMU AND KASHMIR   (Pakistan)

Author keywords

Breast cancer; Her 2 Neu oncogene; Overall survival; Pakistan; Postmenopausal; Receptor status

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADOLESCENT; ADULT; AGE; AGED; BREAST TUMOR; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84929377401     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.3.1019     Document Type: Article

References (25)

1. Abedayo A, Onitillo, Jessica M, et al (2009). Breast cancer subtypes based on ER, PR and Her 2 expression: comparison of clinicopathological features and survival. Clinical Medicine and Research, 7, 4-13.
2. Almasri NM, Al Hamad M (2005). Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res, 7, 598-604.
3. Nuclear Medicine, Oncology and Radiotherapy Institute (NORI) (2010-2012) Annual Report. Islamabad, 19.
4. Asif HM, Sultana S, Akhtar N, et al (2014). Prevalence, risk factors and disease knowledge of breast cancer in Pakistan. Asian Pac J Cancer Prev, 15, 4411-16.
5. Ayadi L, Khabir A, Amouri H, et al (2008). Correlation of HER-2 over-expression with clinicopathological parameters in Tunisian breast carcinoma. World J Surg Oncol, 6, 112-9.
6. Bekir K, Mithat C, Chamlibel M, et al (2003). Prognostic factors affecting survival and disease free survival in lymph node negative breast carcinoma. J Sur Oncology, 83, 167-72.
7. Christine L, Carol A, Donald H (1989). Relation of tumor size, lymph node status and survival in 24, 740 breast cancer cases. Cancer, 63, 181-7.
8. Cianfrocca M, Goldstein LJ (2004). Prognostic and predictive factors in early stage breast cancer. The oncologist, 9, 606-16.
9. Goksu SS, Tastekin D, Arslan D, et al (2014). Clinicopathological features and molecular subtypes of breast cancer in young women (age < 35). Asian Pac J Cancer Prev, 15, 6665-8.
10. Goldhrisch A, Glick JH, Gelber RD, et al (2005). Meeting highlights: International expert consensus on the primary therapy of early breast cancer. Ann Oncol, 16, 1569-583.
11. Goldhrisch A, Wood WC, Geber RD, et al (2007). Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer. Annals of Oncology, 18, 1133-44.
12. Goyanes RI, Perez XE, Rodriguez RC, et al (2010). Hormone receptors and other prognostic factors in breast cancer in Cuba. MEDICC review, 12, 36-40.
13. Guth U, Wight E, Schotzau A, et al (2005). Breast carcinoma with non inflammatory skin involvement T4b: time to abandon an historic relic from TNM classification. Cancer, 104, 1862-70.
14. Hussein O, Mosbah M, Farouk O, et al (2013). Hormone receptors and age distibution in breast cancer patients at university hospital in northern Egypt. Breast Cancer: Basic Clin Res, 7, 51-57.
15. Jafari-Koshki T, Mansourian M, Mokarian F (2014). Exploring factors related to metastasis free survival in breast cancer patients using Bayesian cure models. Asian Pac J Cancer Prev, 15, 9673-78.
16. Kaptain S, Tan LK, Chen B (2001). Her-2/neu and breast cancer. DiagnMolPathol, 10, 139-52.
17. Kariya S, Ogawa Y, Nishioka A, et al (2005). Relationship between hormonal receptors, HER-2, p53 protein, bcl-2, and MIB-1 status and the antitumor effects of neoadjuvantanthracycline-based chemotherapy in invasive breast cancer patients. Radiat Med, 23, 189-94.
18. Maksimovic S (2009). Prognostic value HER-2/neu expression inT1 to T3 breast cancer with axillary lymph node metastasis, Breast Cancer Res, 11 (Suppl 1), 9.
19. Meng L, Maskarinec G, Wilkens L (1997). Ethnic differences and factors related to breast cancer survival in Hawaii. Int J Epidemiology, 26, 1151-58.
20. Michaelson JS, Silvesterstein M, Sgroi D, et al (2003). The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer, 98, 2133-43.
21. Nair MK, Sankaranarayanan R, Nair KS, et al (1993). Overall survival from breast cancer in Kerala, India, in relation to menstrual, clinical and reproductive factors. Cancer, 71, 1791-6.
22. Rezaienzadeh A, Talei AR, Rejaeefard AR, et al (2012). Vascular invasion as an independent prognostic factor in lymph node negative invasive breast cancer. Asian Pacific J Cancer Prev, 13, 5767-72.
23. Shim HJ, Kim SH, Kang BJ, et al (2014). Breast cancer recurrence according to molecular subtype. Asian Pac J Cancer Prev, 15, 5539-44.
24. Tada K, Morizono H, Iijima K, et al (2008). Skin invasion and prognosis in node negative breast cancer: a retrospective study. World J Surg Oncol, 6.
25. Vaz-Luis I, Ottessen RA, Hughes ME, et al (2012). Impact of hormone receptor status on breast cancer recurrence and clinical outcomes among patients with human epidermal growth factor 2 positive breast cancer in the National comprehensive cancer network. Breast Cancer Res, 14, R129.